Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 455 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Statin Clear all
Recruiting Phase 2 Interventional

Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)

NCT05483010
View directory record Official record
Conditions
Clonal Cytopenia of Undetermined Significance, Myelodysplastic Syndromes
Interventions
Atorvastatin, Rosuvastatin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 17, 2026, 4:03 PM EDT
Completed Phase 4 Interventional Results available

Telephone Based Management of Hyperlipidemia

NCT01212159
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Self Monitoring Lipid Analyzer
Device
Lead sponsor
Temple University
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 17, 2026, 4:03 PM EDT
Terminated Phase 3 Interventional

Efficacy of Lapaquistat Acetate Alone or Combined With High-Dose Statin Therapy in Subjects With Hypercholesterolemia

NCT00249899
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Lapaquistat acetate and stable statin therapy, Stable statin therapy
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
13
States / cities
Santa Ana, California • Chicago, Illinois • Iowa City, Iowa + 10 more
Source: ClinicalTrials.gov public record
Updated May 24, 2012 · Synced Oct 17, 2026, 4:03 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Pharmacogenomic Modulators of Impaired Exercise Adaptation in Statin Users

NCT04636138
View directory record Official record
Conditions
HMG-CoA Reductase Inhibitor Toxicity
Interventions
Exercise
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
35 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 17, 2026, 4:03 PM EDT
Completed Phase 4 Interventional Results available

EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders)

NCT05742841
View directory record Official record
Conditions
Lipid Disorder
Interventions
moderate- or high-intensity statin/ rosuvastatin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 17, 2026, 4:03 PM EDT
Completed Phase 2 Interventional

Comparison of SLx-4090 Combined With Statin Therapy Versus Statin Alone in Reducing LDL-C in Patients With Hyperlipidemia

NCT00810979
View directory record Official record
Conditions
Hyperlipidemia
Interventions
SLx-4090, Placebo, Statin
Drug · Other
Lead sponsor
Response Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
19
States / cities
Birmingham, Alabama • Tempe, Arizona • Tucson, Arizona + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 17, 2026, 4:03 PM EDT
Terminated Phase 4 Interventional Results available

Accelerated Atherosclerosis in High Risk Population Groups: An Assessment by Magnetic Resonance Imaging

NCT02114697
View directory record Official record
Conditions
Atherosclerosis
Interventions
Statin therapy, Lifestyle modification
Drug · Behavioral
Lead sponsor
Emory University
Other
Eligibility
22 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 17, 2026, 4:03 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)

NCT02585778
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
Alirocumab, Placebo, Lipid-Modifying Therapy (LMT), Antihyperglycemic Drug
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
29
States / cities
Encino, California • Fresno, California • Oakland, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 17, 2026, 4:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Statin Distribution

NCT02360826
View directory record Official record
Conditions
Drug Distribution
Interventions
Pravastatin, Simvastatin
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
8 Years to 21 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 17, 2026, 4:03 PM EDT
Completed Phase 2 Interventional

Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With Hypertriglyceridemia

NCT05889156
View directory record Official record
Conditions
High Triglycerides
Interventions
NST-1024, Placebo
Drug · Other
Lead sponsor
NorthSea Therapeutics B.V.
Industry
Eligibility
18 Years to 79 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
31
States / cities
Birmingham, Alabama • Daphne, Alabama • Tempe, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 17, 2026, 4:03 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Cross-Over Study to Compare the Pharmacokinetics and Pharmacodynamics of LIB003 Process 1 and Process 2 Drug Product

NCT05234775
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
lerodalcibep
Drug
Lead sponsor
LIB Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Oct 17, 2026, 4:03 PM EDT
Completed Phase 2 Interventional Results available

Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

NCT01527045
View directory record Official record
Conditions
Aggressive Non-Hodgkin Lymphoma, Blasts Under 5 Percent of Bone Marrow Nucleated Cells, Chronic Lymphocytic Leukemia, Loss of Chromosome 17p, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Prolymphocytic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Aggressive Adult Non-Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia
Interventions
Atorvastatin Calcium, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Total-Body Irradiation
Drug · Other · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Denver, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 17, 2026, 4:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Statin Use on Aldosterone Secretion

NCT02871687
View directory record Official record
Conditions
Healthy Subjects
Interventions
Simvastatin, Pravastatin, Placebo
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Oct 17, 2026, 4:03 PM EDT
Completed Not applicable Interventional

Habit Formation for Adherence to Statin Use and LDL Reduction

NCT01798784
View directory record Official record
Conditions
Medication Adherence
Interventions
Sweepstake Incentive 1, Sweepstake Incentive 2, Sweepstake Incentive 3
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Oct 17, 2026, 4:03 PM EDT
Completed Not applicable Interventional

The Use of Mobile Health Technology and Behavioral Economics to Encourage Adherence in Adolescents

NCT04458766
View directory record Official record
Conditions
Familial Hypercholesterolemia, Adherence, Medication
Interventions
Monetary incentives
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
12 Years to 21 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 17, 2026, 4:03 PM EDT
Terminated Not applicable Interventional Results available

Effects of Statins on Lower Extremity Arterial Function Assessed by Magnetic Resonance Imaging

NCT00770679
View directory record Official record
Conditions
Diabetes
Interventions
lipitor
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 17, 2026, 4:03 PM EDT
Completed Phase 4 Interventional

Efficacy of Almonds Added to Chronic Statin Therapy

NCT00603876
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Almonds
Dietary Supplement
Lead sponsor
University of Kansas
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Kansas City, Kansas • Shawnee, Kansas
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Oct 17, 2026, 4:03 PM EDT
Completed Not applicable Interventional

The Triglyceride Lowering Effect of an Omega-3 Fat (DHA) in Addition to Statin Therapy for Patients With CAD or Diabetes

NCT00360217
View directory record Official record
Conditions
Hypertriglyceridemia (TG>200<500), Hyperlipidemia, Coronary Artery Disease, Coronary Risk Equivalent, Diabetes
Interventions
docosahexanoic acid (DHA)
Drug
Lead sponsor
Maine Center for Lipids and Cardiovascular Health
Other
Eligibility
21 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Scarborough, Maine
Source: ClinicalTrials.gov public record
Updated Nov 18, 2011 · Synced Oct 17, 2026, 4:03 PM EDT
Completed Phase 4 Interventional

A Randomized Evaluation of First-dollar Coverage for Post-MI Secondary Preventive Therapies

NCT00566774
View directory record Official record
Conditions
Myocardial Infarction, Coronary Artery Disease
Interventions
Full drug coverage, Usual coverage
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
5,860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 11, 2016 · Synced Oct 17, 2026, 4:03 PM EDT
Completed Phase 2 Interventional

Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol

NCT00701883
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Placebo, MBX-8025, Atorvastatin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Huntington Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2015 · Synced Oct 17, 2026, 4:03 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy

NCT05266586
View directory record Official record
Conditions
Dyslipidemias, High Cholesterol, Hypercholesterolemia
Interventions
Obicetrapib, Ezetimibe 10mg, Obicetrapib placebo, Ezetimibe placebo
Drug · Other
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
16
States / cities
Los Angeles, California • Northridge, California • Ocala, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 17, 2026, 4:03 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Investigation of a Patient Support Intervention for Statin Medication Adherence

NCT06972979
View directory record Official record
Conditions
Medication Adherence
Interventions
Text Message Gamification and Remote Support
Behavioral
Lead sponsor
Ascension Health
Industry
Eligibility
18 Years and older
Enrollment
2,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 17, 2026, 4:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Vascepa to Accelerate Lipoprotein Uptake and Elimination

NCT03885661
View directory record Official record
Conditions
Lipid Disorder, Triglycerides High, Dyslipidemias
Interventions
Icosapent Ethyl 1000 MG [Vascepa]
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Oct 17, 2026, 4:03 PM EDT
Completed Phase 2 Interventional Results available

A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)

NCT04516291
View directory record Official record
Conditions
Dyslipidemias, Hyperlipidemias, Hyperlipoproteinemias
Interventions
Vupanorsen, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
59
States / cities
Gilbert, Arizona • Little Rock, Arkansas • Lincoln, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Oct 17, 2026, 4:03 PM EDT